Tuesday, September 26, 2017 10:15 PM ET
Insider Makes Sale of Selecta Biosciences (SELB) Shares Slowing 90 Day Buying Trend
There was a notable sale of shares of Selecta Biosciences by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Amir Nashat, Director — sold 79,211 shares in the company having a market value of approximately $1,515,664. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 338,791 company shares and the disposition of 154,073 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net purchases of 105,507 shares and have averaged 143,019 shares per transaction over this time period.
Relative to its peers over the last 90 days, insider buy/sell trading at Selecta Biosciences is above the 266-company peer group average. Bio Therapeutic Drugs peer group saw 306 buy/sell trades during this period for an average of 1.2 transactions per company. The number of shares per buy/sell trade for Selecta Biosciences insiders was also higher. Within the peer group there were 9,239,272 shares purchased and 16,879,465 shares sold with company insiders having sold 24,968 shares on average.
Insider buying and selling activity that is significant has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in composing and writing this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at email@example.com. Copyright 2017 UpTick Data Technologies. All rights reserved.